ACS chemical neuroscience molecule spotlight on dimebon.
Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer's disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.
Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, USA.
Corey R
CR
Hopkins
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000453:epidemiology; D000818:Animals; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000627:therapeutic use*; D009488:Neurosciences; D012958:Societies, Scientific
D007211:Indoles; C010119:latrepirdine